NASDAQ:GDTC CytoMed Therapeutics (GDTC) Stock Price, News & Analysis $2.33 +0.03 (+1.30%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock About CytoMed Therapeutics Stock (NASDAQ:GDTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytoMed Therapeutics alerts:Sign Up Key Stats Today's Range$2.30▼$2.4150-Day Range$2.20▼$2.8152-Week Range$1.20▼$4.05Volume5,338 shsAverage Volume77,567 shsMarket Capitalization$25.49 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewCytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Read More… CytoMed Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreGDTC MarketRank™: CytoMed Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 553rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCytoMed Therapeutics has received no research coverage in the past 90 days.Read more about CytoMed Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCytoMed Therapeutics has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.82% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in CytoMed Therapeutics has recently decreased by 6.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoMed Therapeutics does not currently pay a dividend.Dividend GrowthCytoMed Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.82% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in CytoMed Therapeutics has recently decreased by 6.80%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.37 News SentimentCytoMed Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CytoMed Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.04% of the stock of CytoMed Therapeutics is held by institutions.Read more about CytoMed Therapeutics' insider trading history. Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GDTC Stock News HeadlinesCytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate UpdatesApril 28, 2025 | globenewswire.comCytoMed Therapeutics (NASDAQ:GDTC) Trading Down 7.3% - Here's WhyApril 22, 2025 | americanbankingnews.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 2, 2025 | Brownstone Research (Ad)CytoMed Therapeutics announces Chairman's Letter to the Company's shareholdersFebruary 6, 2025 | globenewswire.comCytoMed Therapeutics Expands Leadership Amid Strategic GrowthDecember 5, 2024 | tipranks.comCytoMed Therapeutics Limited (GDTC)July 19, 2024 | finance.yahoo.comCytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid CancersJuly 17, 2024 | globenewswire.comCytoMed Therapeutics Ltd GDTCMarch 27, 2024 | morningstar.comSee More Headlines GDTC Stock Analysis - Frequently Asked Questions How have GDTC shares performed this year? CytoMed Therapeutics' stock was trading at $3.40 at the beginning of 2025. Since then, GDTC stock has decreased by 30.7% and is now trading at $2.3550. View the best growth stocks for 2025 here. When did CytoMed Therapeutics IPO? CytoMed Therapeutics (GDTC) raised $10 million in an IPO on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share. How do I buy shares of CytoMed Therapeutics? Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoMed Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU). Company Calendar Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GDTC CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+112.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio21.54 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book3.02Miscellaneous Outstanding Shares10,940,000Free FloatN/AMarket Cap$25.76 million OptionableNot Optionable Beta-0.26 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:GDTC) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.